Virological Response and Safety of Combination Treatment with Bulevirtide and Pegylated Interferon in Chronic Hepatitis D Patients with Advanced Fibrosis/Cirrhosis: 48 Weeks Interim Results from SEE-D Trial

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
May 7-10, 2025
Amsterdam the Netherlands


Virological Response and Safety of Combination Treatment with Bulevirtide and Pegylated Interferon in Chronic Hepatitis D Patients with Advanced Fibrosis/Cirrhosis: 48 Weeks Interim Results from SEE-D Trial

	EASL 2025 May 7-10 Amsterdam